A phase 1/2 dose escalation trial of multiple doses of MLN2704 (DM1 conjugated monoclonal antibody MLN591) in subjects with metastatic androgen-independent prostate cancer

Trial Profile

A phase 1/2 dose escalation trial of multiple doses of MLN2704 (DM1 conjugated monoclonal antibody MLN591) in subjects with metastatic androgen-independent prostate cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2007

At a glance

  • Drugs MLN 2704 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jul 2007 Status changed from in progress to completed.
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top